Thermo Fisher Scientific Inc. (TMO) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Thermo Fisher Scientific financial statements at a glance

Thermo Fisher Scientific reported revenue of $44.56 billion for fiscal year 2025 (ended December 31, 2025), up 3.9% from fiscal year 2024. Net income was $6.70 billion, a net margin of 15.0%, and diluted earnings per share were $17.74.

At the end of fiscal year 2025 it had total assets of $110.34 billion, total liabilities of $56.81 billion and shareholders' equity of $53.41 billion, with cash and short-term investments of $10.11 billion and total debt of $39.39 billion.

Its operations brought in $7.82 billion of cash; capital spending was $1.53 billion, leaving free cash flow of $6.29 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

TMO logo

Thermo Fisher Scientific Inc.

TMOUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
44.56B
Prev Year: 42.88B
YoY: +3.9%
Operating Revenue
44.56B
Prev Year: 42.88B
YoY: +3.9%
Reconciled Depreciation
2.78B
Prev Year: 3.11B
YoY: -10.6%
Net Income from Continuing Operation Net Minority Interest
6.70B
Prev Year: 6.33B
YoY: +5.8%
Total Unusual Items Excluding Goodwill
-349.00M
Prev Year: -358.00M
YoY: +2.5%
Total Unusual Items
-349.00M
Prev Year: -358.00M
YoY: +2.5%
Normalized EBITDA
11.86B
Prev Year: 11.89B
YoY: -0.3%
Tax Rate for Calcs
0.075
Prev Year: 0
Tax Effect of Unusual Items
-26.18M
Prev Year: -33.29M
YoY: +21.4%
Cost of Revenue
26.32B
Prev Year: 25.18B
YoY: +4.5%
Gross Profit
18.24B
Prev Year: 17.70B
YoY: +3.0%
Operating Expense
10.13B
Prev Year: 9.98B
YoY: +1.4%
Selling General and Administrative
8.73B
Prev Year: 8.60B
YoY: +1.6%
Research and Development
1.40B
Prev Year: 1.39B
YoY: +0.5%
Operating Income
8.11B
Prev Year: 7.72B
YoY: +5.1%
Net Non Operating Interest Income Expense
-426.00M
Prev Year: -312.00M
YoY: -36.5%
Non-operating Interest Income
993.00M
Prev Year: 1.08B
YoY: -7.9%
Non-operating Interest Expense
1.42B
Prev Year: 1.39B
YoY: +2.1%
Other Income Expense
-374.00M
Prev Year: -367.00M
YoY: -1.9%
Gain on Sale of Securities
13.00M
Prev Year: 21.00M
YoY: -38.1%
Special Income Charges
-362.00M
Prev Year: -379.00M
YoY: +4.5%
Restructuring and Mergers Acquisition
362.00M
Prev Year: 379.00M
YoY: -4.5%
Other Non-operating Income (expense)
-25.00M
Prev Year: -9.00M
YoY: -177.8%
Pre-tax Income
7.31B
Prev Year: 7.04B
YoY: +3.9%
Provision for Income Taxes
547.00M
Prev Year: 657.00M
YoY: -16.7%
Equity in Earnings of Affiliates, Net of Tax
-41.00M
Prev Year: -42.00M
YoY: +2.4%
Net Income Common Stockholders
6.70B
Prev Year: 6.33B
YoY: +5.8%
Net Income
6.70B
Prev Year: 6.33B
YoY: +5.8%
Net Income Including Non-Controlling Interests
6.72B
Prev Year: 6.34B
YoY: +6.0%
Net Income from Continuing Operations
6.72B
Prev Year: 6.34B
YoY: +6.0%
Noncontrolling Interests
-17.00M
Prev Year: -3.00M
YoY: -466.7%
Diluted NI Available to Com Stockholders
6.70B
Prev Year: 6.33B
YoY: +5.8%
Basic EPS
17.77
Prev Year: 16.523
YoY: +7.5%
Diluted EPS
17.74
Prev Year: 16.53
YoY: +7.3%
Weighted Average Shares (basic)
377.00M
Prev Year: 382.00M
YoY: -1.3%
Weighted Average Shares (diluted)
378.00M
Prev Year: 383.00M
YoY: -1.3%
Total Operating Income as Reported
7.75B
Prev Year: 7.34B
YoY: +5.6%
Total Expenses
36.45B
Prev Year: 35.16B
YoY: +3.7%
Net Income from Continuing and Discontinued Operation
6.70B
Prev Year: 6.33B
YoY: +5.8%
Normalized Income
7.03B
Prev Year: 6.66B
YoY: +5.5%
Interest Income
993.00M
Prev Year: 1.08B
YoY: -7.9%
Interest Expense
1.42B
Prev Year: 1.39B
YoY: +2.1%
Net Interest Income
-426.00M
Prev Year: -312.00M
YoY: -36.5%
EBIT
8.73B
Prev Year: 8.43B
YoY: +3.6%
EBITDA
11.51B
Prev Year: 11.54B
YoY: -0.2%
Reconciled Cost of Revenue
26.32B
Prev Year: 25.18B
YoY: +4.5%
Values in USD

Thermo Fisher Scientific key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$44.6B$42.9B$42.9B$44.9B$39.2B
Gross profit$18.2B$17.7B$17.1B$19.0B$19.6B
Operating income$8.1B$7.7B$7.3B$8.5B$10.2B
Net income$6.7B$6.3B$6.0B$7.0B$7.7B
Diluted EPS$17.74$16.53$15.45$17.63$19.46
Total assets$110.3B$97.3B$98.7B$97.2B$95.1B
Total liabilities$56.8B$47.6B$51.9B$53.0B$54.1B
Shareholders' equity$53.4B$49.6B$46.7B$44.0B$40.8B
Cash and short-term investments$10.1B$5.6B$8.1B$8.5B$4.5B
Total debt$39.4B$31.3B$34.9B$34.5B$34.9B
Operating cash flow$7.8B$8.7B$8.4B$9.2B$9.3B
Capital spending$1.5B$1.4B$1.5B$2.2B$2.5B
Free cash flow$6.3B$7.3B$6.9B$6.9B$6.8B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Thermo Fisher Scientific's revenue in fiscal year 2025?

$44.56 billion, up 3.9% from $42.88 billion in fiscal year 2024.

How much profit does Thermo Fisher Scientific make?

Thermo Fisher Scientific reported net income of $6.70 billion for fiscal year 2025 (15.0% of revenue); operating income was $8.11 billion.

How much cash and debt does Thermo Fisher Scientific have?

At the end of fiscal year 2025: cash and short-term investments of $10.11 billion and total debt of $39.39 billion.

What is Thermo Fisher Scientific's free cash flow?

$6.29 billion in fiscal year 2025 (operating cash flow of $7.82 billion minus capital spending of $1.53 billion).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube